Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Veracity Capital LLC

Veracity Capital LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 8.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,614 shares of the medical research company’s stock after acquiring an additional 123 shares during the quarter. Veracity Capital LLC’s holdings in Amgen were worth $459,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Amgen by 0.3% during the third quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock valued at $13,178,910,000 after purchasing an additional 165,636 shares during the period. Price T Rowe Associates Inc. MD raised its position in Amgen by 3.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,564,710 shares of the medical research company’s stock worth $1,890,769,000 after acquiring an additional 243,720 shares in the last quarter. Royal Bank of Canada increased its stake in Amgen by 14.8% in the 4th quarter. Royal Bank of Canada now owns 5,831,624 shares of the medical research company’s stock worth $1,679,625,000 after purchasing an additional 751,947 shares in the last quarter. Norges Bank purchased a new position in Amgen in the 4th quarter worth about $1,556,912,000. Finally, California Public Employees Retirement System grew its stake in Amgen by 22.0% during the 4th quarter. California Public Employees Retirement System now owns 2,716,088 shares of the medical research company’s stock valued at $782,288,000 after acquiring an additional 490,539 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on AMGN. Raymond James assumed coverage on Amgen in a report on Thursday, March 28th. They issued a “market perform” rating for the company. Royal Bank of Canada upped their price target on Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a research note on Friday, June 14th. Morgan Stanley raised their price target on Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research report on Friday, May 3rd. William Blair upgraded Amgen from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. Finally, Mizuho lifted their target price on Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a research note on Thursday, May 9th. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $307.35.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.69% of the stock is owned by company insiders.

Amgen Stock Down 0.1 %

Shares of NASDAQ:AMGN opened at $308.97 on Friday. The company has a market capitalization of $165.74 billion, a price-to-earnings ratio of 44.20, a P/E/G ratio of 2.79 and a beta of 0.58. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98. The business’s 50-day moving average is $304.61 and its 200-day moving average is $293.03. Amgen Inc. has a 1 year low of $218.44 and a 1 year high of $329.72.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The business had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. During the same period in the prior year, the business earned $3.98 EPS. The firm’s revenue for the quarter was up 22.0% on a year-over-year basis. Equities research analysts predict that Amgen Inc. will post 19.47 earnings per share for the current year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.